1-benzyl-2-thio-5,6-dihydrouracil
Description
1-Benzyl-2-thio-5,6-dihydrouracil is a synthetic compound that belongs to the class of **thiazolidine-2,4-diones**, also known as **TZDs**.
**Here's what makes it interesting for research:**
* **Analogous to natural compounds:** It shares structural similarities with natural compounds like thiazolidinedione (TZD) derivatives, which have been shown to exhibit a variety of biological activities.
* **Potential for biological activity:** TZDs, like 1-benzyl-2-thio-5,6-dihydrouracil, are being studied for their potential in various therapeutic applications, including:
* **Antidiabetic activity:** Some TZDs have been found to improve insulin sensitivity and glucose utilization, which makes them promising agents for the treatment of type 2 diabetes.
* **Anti-inflammatory activity:** TZDs have shown anti-inflammatory properties and are being investigated for their potential in treating inflammatory diseases.
* **Anti-cancer activity:** Certain TZDs are being explored for their ability to inhibit the growth and spread of cancer cells.
* **Versatile scaffold:** The structure of 1-benzyl-2-thio-5,6-dihydrouracil can be readily modified by introducing different substituents at various positions, making it a versatile scaffold for synthesizing a wide array of TZDs with varying biological activities.
**Important research areas:**
* **Drug discovery:** Researchers are actively exploring the synthesis and biological evaluation of 1-benzyl-2-thio-5,6-dihydrouracil and its derivatives to discover novel therapeutic agents for various diseases.
* **Structure-activity relationship (SAR):** Studying how modifications to the structure of 1-benzyl-2-thio-5,6-dihydrouracil affect its biological activity is crucial for optimizing the design of new TZDs.
* **Mechanism of action:** Understanding the molecular mechanisms by which 1-benzyl-2-thio-5,6-dihydrouracil and its derivatives exert their biological effects is essential for developing targeted therapies.
**Note:** While 1-benzyl-2-thio-5,6-dihydrouracil shows potential, it's important to emphasize that the compound is still under research and its safety and efficacy haven't been fully established. Further studies are needed before it can be considered for clinical use.
1-benzyl-2-thio-5,6-dihydrouracil: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 823208 |
MeSH ID | M0040319 |
Synonyms (25)
Synonym |
---|
HMS1683N05 |
1-benzyl-2-sulfanylidene-1,3-diazinan-4-one |
nsc50193 |
19341-60-7 |
nsc-50193 |
mls002667345 , |
BAS 00404062 |
smr001557112 |
AKOS000505115 |
4(1h)-pyrimidinone, tetrahydro-1-(phenylmethyl)-2-thioxo- |
AKOS005748723 |
HMS3079G20 |
nsc 50193 |
9y8r3kr42q , |
unii-9y8r3kr42q |
1-benzyl-2-thio-5,6-dihydrouracil |
STL148396 |
1-benzyl-2-sulfanyl-5,6-dihydropyrimidin-4(1h)-one |
DTXSID90172947 |
SR-01000318742-1 |
sr-01000318742 |
tetrahydro-1-(phenylmethyl)-2-thioxo-4(1h)-pyrimidinone |
hydrouracil, 1-benzyl-2-thio- |
1-benzylhydrouracil |
BRD-K60484785-001-05-8 |
Bioassays (13)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |